Nanotechnology platforms in Parkinson’s Disease
نویسندگان
چکیده
منابع مشابه
Automatic, unsupervised classification of dyskinesia in patients with Parkinsons Disease
One of the characteristic symptoms of patients with Parkinson Disease (PD) is a rigidity of movement. These symptoms disappear after administration of Levodopa. However, the long-term use of levodopa causes involuntary movements (dyskinesia). A proper diagnosis requires an automatic, unsupervised method for the detection and classification of levodopa induced dyskinesia. The main problem, howev...
متن کاملNanotechnology platforms and physiological challenges for cancer therapeutics.
Nanotechnology is considered to be an emerging, disruptive technology that will have significant impact in all industrial sectors and across-the-board applications in cancer research. There has been tremendous investment in this area and an explosion of research and development efforts in recent years, particularly in the area of cancer research. At the National Institutes of Health, nanomedici...
متن کاملManual Therapy Choices: A General Approach to Parkinsons Disease
In treating dysfunction, it is normal for most therapists to use a variety of modalities and methods including myofascial release, muscle-energy techniques, positional-release techniques and many more. The assumption must be that different tools achieve different effects, and the ones we choose reflect our perception as to the needs of the individual and/or of the tissues involved. Sledgehammer...
متن کاملParkinsons Disease Classification using Neural Network and Feature Selection
In this study, the Multi-Layer Perceptron (MLP)with Back-Propagation learning algorithm are used to classify to effective diagnosis Parkinsons disease(PD).It’s a challenging problem for medical community.Typically characterized by tremor, PD occurs due to the loss of dopamine in the brains thalamic region that results in involuntary or oscillatory movement in the body. A feature selection algor...
متن کاملNanotechnology for Alzheimer’s Disease Detection
Alzheimer’s disease (AD) is the most common cause of dementia among people of age 65 and older. The diagnosis of sporadic AD is based on clinical exclusion criteria and is only definite at necropsy. So, biochemical markers for AD would be of great value for its early diagnosis. During the last decade, research efforts have focused on developing cerebrospinal fluid (CSF) biomarkers for AD. The d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ADMET & DMPK
سال: 2015
ISSN: 1848-7718
DOI: 10.5599/admet.3.3.189